Bicara Therapeutics (NASDAQ:BCAX) Earns “Outperform” Rating from Wedbush

Bicara Therapeutics (NASDAQ:BCAX)‘s stock had its “outperform” rating reaffirmed by equities researchers at Wedbush in a report released on Monday,RTT News reports. They currently have a $30.00 price objective on the stock. Wedbush’s price target suggests a potential upside of 104.92% from the company’s current price.

A number of other analysts also recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Tuesday, October 14th. Piper Sandler started coverage on shares of Bicara Therapeutics in a research note on Monday, August 18th. They set an “overweight” rating and a $36.00 price objective on the stock. Finally, HC Wainwright decreased their target price on shares of Bicara Therapeutics from $41.00 to $40.00 and set a “buy” rating on the stock in a report on Friday, August 22nd. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Bicara Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $29.17.

Bicara Therapeutics Stock Up 0.5%

Shares of NASDAQ:BCAX opened at $14.64 on Monday. Bicara Therapeutics has a 12-month low of $7.80 and a 12-month high of $24.70. The company’s 50 day moving average price is $14.65 and its two-hundred day moving average price is $12.54. The firm has a market cap of $799.49 million, a PE ratio of -4.62 and a beta of -0.76.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.12). On average, research analysts expect that Bicara Therapeutics will post -2.59 EPS for the current year.

Insider Transactions at Bicara Therapeutics

In related news, COO Ryan Cohlhepp sold 39,600 shares of the firm’s stock in a transaction on Monday, October 6th. The stock was sold at an average price of $18.06, for a total transaction of $715,176.00. Following the sale, the chief operating officer owned 205,541 shares of the company’s stock, valued at $3,712,070.46. This trade represents a 16.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider David Raben sold 22,000 shares of the company’s stock in a transaction dated Thursday, October 9th. The stock was sold at an average price of $18.45, for a total value of $405,900.00. Following the completion of the transaction, the insider directly owned 35,497 shares of the company’s stock, valued at approximately $654,919.65. The trade was a 38.26% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 146,534 shares of company stock valued at $2,682,012 over the last quarter.

Institutional Investors Weigh In On Bicara Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. CWM LLC bought a new position in shares of Bicara Therapeutics during the first quarter valued at $29,000. Legal & General Group Plc grew its stake in shares of Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after purchasing an additional 1,233 shares during the last quarter. Ameritas Investment Partners Inc. increased its holdings in Bicara Therapeutics by 73.0% in the second quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock valued at $32,000 after purchasing an additional 1,474 shares during the period. Tower Research Capital LLC TRC raised its position in Bicara Therapeutics by 419.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after purchasing an additional 3,866 shares during the last quarter. Finally, New York State Common Retirement Fund acquired a new position in Bicara Therapeutics during the 1st quarter worth about $52,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.